Table 1.
Key oncological biologics whose patents either have expired or will expire soon
| Biologic (brand name) | Manufacturer | Estimated patent expiry (month and year) | |
|---|---|---|---|
| United States | Europe | ||
| Supportive agents | |||
| Filgrastim (Neupogen) | Amgen/Roche/Jassen | Expired | Expired |
| Pegfilgrastim (Neulasta) | Amgen | Expired | Aug 2017 |
| Epoetin alfa (Emprex/Epogen/Procrit) | Amgen/Jassen | Expired | Expired |
| Darbepoetin alfa (Aranesp) | Amgen | May 2024 | Jul 2016 |
| Monoclonal antibodies | |||
| Trastuzumab (Herceptin) | Genentech/Roche | Jun 2019 | Expired |
| Rituximab (Rituxan/MabThera) | Roche | Sep 2016 | Expired |
| Cetuximab (Erbitux) | Eli Lilly/Bristol-Myers Squibb/Merck KgaA |
Expired | Expired |
| Bevacizumab (Avastin) | Genentech/Roche | Jul 2019 | Jan 2022 |